Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816632 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL29504152 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL29728563 | 0.92 | CHRM2 (0.49) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL29411118 | 0.90 | DPP4 (0.53) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL12135710 | 0.90 | DPP4 (0.53) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL29411145 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL31497255 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL29816377 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL30785833 | 0.89 | BDKRB2 (0.38) | DPP4DPP8DPP9CHRM3CHRM2 | |
| SCHEMBL31135206 | 0.88 | CHRM2 (0.49) | DPP4DPP8DPP9CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-11433112-B1 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-11426440-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | DPP4 852/4885DPP8 2138/4885DPP9 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.